The transgene was designed with the tetracycline-responsive element (TRE; also called tet-operator or tetO) upstream of a rat vascular chymase (RVCH or Mcpt1) gene modified such that a human influenza hemagglutinin (HA) tag is added to the C terminus of mature RVCH protein. With the addition of dox expression of the RVCH-HA fusion protein can be completely abolished, reversing the hypertension phenotype.